Datasets:
Upload domains/icd10-metabolic/learning-graph.csv with huggingface_hub
Browse files
domains/icd10-metabolic/learning-graph.csv
ADDED
|
@@ -0,0 +1,71 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
ConceptID,ConceptLabel,Dependencies,TaxonomyID
|
| 2 |
+
1,ICD-10 Classification,,FOUND
|
| 3 |
+
2,Chapter IV Endocrine Nutritional Metabolic,1,CHAPTER
|
| 4 |
+
3,Thyroid Gland Disorders,2,BLOCK
|
| 5 |
+
4,Diabetes Mellitus,2,BLOCK
|
| 6 |
+
5,Other Glucose Regulation Disorders,2,BLOCK
|
| 7 |
+
6,Obesity,2,BLOCK
|
| 8 |
+
7,Metabolic Disorders,2,BLOCK
|
| 9 |
+
8,Nutritional Deficiencies,2,BLOCK
|
| 10 |
+
9,Hypothyroidism,3,CATEGORY
|
| 11 |
+
10,Hyperthyroidism,3,CATEGORY
|
| 12 |
+
11,Thyroiditis,3,CATEGORY
|
| 13 |
+
12,Congenital Hypothyroidism,9,CODE
|
| 14 |
+
13,Primary Hypothyroidism E03,9,CODE
|
| 15 |
+
14,Secondary Hypothyroidism E03.1,9,CODE
|
| 16 |
+
15,Graves Disease E05.0,10,CODE
|
| 17 |
+
16,Toxic Multinodular Goiter E05.2,10,CODE
|
| 18 |
+
17,Type 1 Diabetes Mellitus E10,4,CATEGORY
|
| 19 |
+
18,Type 2 Diabetes Mellitus E11,4,CATEGORY
|
| 20 |
+
19,Gestational Diabetes O24,4,CATEGORY
|
| 21 |
+
20,Other Specified Diabetes E13,4,CATEGORY
|
| 22 |
+
21,T2DM with Diabetic Nephropathy E11.65,18,CODE
|
| 23 |
+
22,T2DM with Diabetic Neuropathy E11.40,18,CODE
|
| 24 |
+
23,T2DM with Diabetic Retinopathy E11.31,18,CODE
|
| 25 |
+
24,T2DM with Diabetic Foot E11.621,18,CODE
|
| 26 |
+
25,T2DM with Hypoglycemia E11.641,18,CODE
|
| 27 |
+
26,T2DM with Hyperglycemia E11.65,18,CODE
|
| 28 |
+
27,HbA1c Clinical Monitoring,18|17,CLINICAL_CONCEPT
|
| 29 |
+
28,Impaired Glucose Tolerance R73.02,5,CODE
|
| 30 |
+
29,Impaired Fasting Glucose R73.01,5,CODE
|
| 31 |
+
30,Prediabetes R73.09,28|29,CODE
|
| 32 |
+
31,Insulin Resistance,30|18,MECHANISM
|
| 33 |
+
32,Metabolic Syndrome E88.81,31|6,CATEGORY
|
| 34 |
+
33,Overweight E66.9,6,CATEGORY
|
| 35 |
+
34,Obesity Class I BMI 30-35 E66.09,6,CODE
|
| 36 |
+
35,Obesity Class II BMI 35-40 E66.01,6,CODE
|
| 37 |
+
36,Obesity Class III BMI Over 40 E66.01,6,CODE
|
| 38 |
+
37,Morbid Obesity E66.01,36,CODE
|
| 39 |
+
38,Obesity Hypoventilation Syndrome E66.2,37,CODE
|
| 40 |
+
39,Lipid Disorders E78,7,BLOCK
|
| 41 |
+
40,Hypercholesterolemia E78.0,39,CODE
|
| 42 |
+
41,Hypertriglyceridemia E78.1,39,CODE
|
| 43 |
+
42,Mixed Hyperlipidemia E78.2,39|40|41,CODE
|
| 44 |
+
43,Low HDL Cholesterol E78.6,39,CODE
|
| 45 |
+
44,Gout M10,7,CATEGORY
|
| 46 |
+
45,Acute Gout M10.00,44,CODE
|
| 47 |
+
46,Chronic Gout M1A,44,CODE
|
| 48 |
+
47,Hyperuricemia E79.0,44,CODE
|
| 49 |
+
48,Electrolyte Disorders,7,CATEGORY
|
| 50 |
+
49,Hyponatremia E87.1,48,CODE
|
| 51 |
+
50,Hypernatremia E87.0,48,CODE
|
| 52 |
+
51,Hypokalemia E87.6,48,CODE
|
| 53 |
+
52,Hyperkalemia E87.5,48,CODE
|
| 54 |
+
53,Vitamin D Deficiency E55,8,CODE
|
| 55 |
+
54,Iron Deficiency E61.1,8,CODE
|
| 56 |
+
55,Iron Deficiency Anemia D50.9,54,CODE
|
| 57 |
+
56,Vitamin B12 Deficiency E53.8,8,CODE
|
| 58 |
+
57,Folate Deficiency E53.8,8,CODE
|
| 59 |
+
58,Protein-Calorie Malnutrition E46,8,CODE
|
| 60 |
+
59,Dehydration E86.0,48,CODE
|
| 61 |
+
60,Acidosis,7,CATEGORY
|
| 62 |
+
61,Metabolic Acidosis E87.2,60,CODE
|
| 63 |
+
62,Diabetic Ketoacidosis E10.10,17|60,CODE
|
| 64 |
+
63,Hyperosmolar Hyperglycemic State E11.01,18|60,CODE
|
| 65 |
+
64,NASH Nonalcoholic Steatohepatitis K75.81,32|18,CODE
|
| 66 |
+
65,Insulin Therapy Concept,17|18,TREATMENT_CONCEPT
|
| 67 |
+
66,Bariatric Surgery Indication,37|18,CLINICAL_CONCEPT
|
| 68 |
+
67,Cardiovascular Risk from Metabolic Disease,32|18|40|41,CLINICAL_CONCEPT
|
| 69 |
+
68,ASCVD Risk Calculator,67,CLINICAL_CONCEPT
|
| 70 |
+
69,Lipid-Lowering Therapy,40|41|42,TREATMENT_CONCEPT
|
| 71 |
+
70,GLP-1 Agonist Indication,18|37|43,TREATMENT_CONCEPT
|